BACKGROUND: Toxicity can lead to noncontinuation of adjuvant endocrine therapy. We hypothesized that endocrine therapy-induced changes in grip strength would predict for early discontinuation of therapy because of musculoskeletal toxicity and would be associated with a patient's body mass index. PATIENTS AND METHODS: Postmenopausal women with breast cancer starting a new adjuvant endocrine therapy were enrolled in the present study. The patients were monitored for 12 months to assess their symptoms, endocrine therapy adherence and change in grip strength and baseline body mass index. The association between the change in grip strength and interval to discontinuation was assessed using a joint longitudinal and survival model. RESULTS: Of the 93 aromatase inhibitor (AI)-treated and 22 tamoxifen-treated patients, 40.9% and 9% discontinued endocrine therapy within 12 months because of toxicity, respectively (P = .019). A trend was seen toward a greater decrease in grip strength in the AI-treated patients over time (P = .055); however, the decrease was not significantly associated with the interval to discontinuation (P = .96). Receipt of an AI (hazard ratio, 5.49; P = .019) and baseline pain (hazard ratio, 1.19; P = .004) significantly decreased the interval to discontinuation. CONCLUSION: In contrast with the findings from previous reports, the change in grip strength in our study was not associated with the interval to discontinuation of AI therapy. Future research should focus on proactive treatment of patients at increased risk of AI intolerance, such as those with high levels of pre-existing pain.
BACKGROUND:Toxicity can lead to noncontinuation of adjuvant endocrine therapy. We hypothesized that endocrine therapy-induced changes in grip strength would predict for early discontinuation of therapy because of musculoskeletal toxicity and would be associated with a patient's body mass index. PATIENTS AND METHODS: Postmenopausal women with breast cancer starting a new adjuvant endocrine therapy were enrolled in the present study. The patients were monitored for 12 months to assess their symptoms, endocrine therapy adherence and change in grip strength and baseline body mass index. The association between the change in grip strength and interval to discontinuation was assessed using a joint longitudinal and survival model. RESULTS: Of the 93 aromatase inhibitor (AI)-treated and 22 tamoxifen-treated patients, 40.9% and 9% discontinued endocrine therapy within 12 months because of toxicity, respectively (P = .019). A trend was seen toward a greater decrease in grip strength in the AI-treated patients over time (P = .055); however, the decrease was not significantly associated with the interval to discontinuation (P = .96). Receipt of an AI (hazard ratio, 5.49; P = .019) and baseline pain (hazard ratio, 1.19; P = .004) significantly decreased the interval to discontinuation. CONCLUSION: In contrast with the findings from previous reports, the change in grip strength in our study was not associated with the interval to discontinuation of AI therapy. Future research should focus on proactive treatment of patients at increased risk of AI intolerance, such as those with high levels of pre-existing pain.
Authors: A Lintermans; B Van Calster; M Van Hoydonck; S Pans; J Verhaeghe; R Westhovens; N L Henry; H Wildiers; R Paridaens; A S Dieudonné; K Leunen; L Morales; K Verschueren; D Timmerman; L De Smet; I Vergote; M R Christiaens; P Neven Journal: Ann Oncol Date: 2011-01-27 Impact factor: 32.976
Authors: Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: N Lynn Henry; Mousumi Banerjee; Max Wicha; Catherine Van Poznak; Jeffrey B Smerage; Anne F Schott; Jennifer J Griggs; Daniel F Hayes Journal: Cancer Date: 2011-06-20 Impact factor: 6.860
Authors: A Lintermans; K Van Asten; H Wildiers; A Laenen; R Paridaens; C Weltens; J Verhaeghe; D Vanderschueren; A Smeets; E Van Limbergen; K Leunen; M R Christiaens; P Neven Journal: Breast Cancer Res Treat Date: 2014-05-11 Impact factor: 4.872
Authors: Ivana Sestak; Jack Cuzick; Francisco Sapunar; Richard Eastell; John F Forbes; Angelo R Bianco; Aman U Buzdar Journal: Lancet Oncol Date: 2008-08-12 Impact factor: 41.316
Authors: Jacquie H Chirgwin; Anita Giobbie-Hurder; Alan S Coates; Karen N Price; Bent Ejlertsen; Marc Debled; Richard D Gelber; Aron Goldhirsch; Ian Smith; Manuela Rabaglio; John F Forbes; Patrick Neven; István Láng; Marco Colleoni; Beat Thürlimann Journal: J Clin Oncol Date: 2016-05-23 Impact factor: 44.544
Authors: Kunal C Kadakia; Claire F Snyder; Kelley M Kidwell; Nicholas J Seewald; David A Flockhart; Todd C Skaar; Zereunesay Desta; James M Rae; Julie L Otte; Janet S Carpenter; Anna M Storniolo; Daniel F Hayes; Vered Stearns; N Lynn Henry Journal: Oncologist Date: 2016-03-23
Authors: Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto Journal: J Clin Oncol Date: 2009-11-30 Impact factor: 44.544
Authors: Daniel L Hertz; Julie A Douglas; Robert M Miller; Kelley M Kidwell; Christina L Gersch; Zeruesenay Desta; Anna Maria Storniolo; Vered Stearns; Todd C Skaar; Daniel F Hayes; N Lynn Henry; James M Rae Journal: Support Care Cancer Date: 2022-07-01 Impact factor: 3.359
Authors: Karen Lisa Smith; Neha Verma; Amanda L Blackford; Jennifer Lehman; Kelly Westbrook; David Lim; John Fetting; Antonio C Wolff; Daniela Jelovac; Robert S Miller; Roisin Connolly; Deborah K Armstrong; Raquel Nunes; Kala Visvanathan; Carol Riley; Katie Papathakis; Nelli Zafman; Jennifer Y Sheng; Claire Snyder; Vered Stearns Journal: NPJ Breast Cancer Date: 2022-04-21
Authors: Daniel L Hertz; Karen Lisa Smith; Yuhua Zong; Christina L Gersch; Andrea M Pesch; Jennifer Lehman; Amanda L Blackford; N Lynn Henry; Kelley M Kidwell; James M Rae; Vered Stearns Journal: Front Genet Date: 2021-06-15 Impact factor: 4.599